Pfizer requires the vaccine for children 5 to 11 years old, but what differs from the adolescent dose
Pfizer has asked the US Food and Drug Administration to authorize the vaccine for children ages 5 to 11.
The news was confirmed by the American media, at a time when parents have expressed concerns about the infection of their children, with the start of the new school year in the classrooms, while the Delta version of the virus continues to spread throughout America and beyond.
The increase in the number of most infected cases has led to an increase in hospitalizations in the US, including young children who are not currently required to be vaccinated.
Meanwhile, last month Pfizer published some data showing that taking two doses of 10 micrograms - or one-third of the dose used for teens and adults - is safe and generates a strong immune response in young children. According to Pfizer officials, the vaccine in that amount produced a good immune response, similar to those aged 16 to 25 years.
Common side effects for teens and adults include fatigue, headaches, muscle aches, fever and nausea.
The company request today could mean the application will not be available until around November as the FDA will also have to review data for that age group as it did for ages 12 to 15.
Pfizer and BioNTech requested the use of the vaccine in adolescents on April 9, and the request was approved by the FDA on May 10.
* CNBC article, translated and adapted into Albanian by Tiranapost.al.